Lutz Harnisch

823 total citations
31 papers, 574 citations indexed

About

Lutz Harnisch is a scholar working on Cardiology and Cardiovascular Medicine, Molecular Biology and Genetics. According to data from OpenAlex, Lutz Harnisch has authored 31 papers receiving a total of 574 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Cardiology and Cardiovascular Medicine, 7 papers in Molecular Biology and 7 papers in Genetics. Recurrent topics in Lutz Harnisch's work include Muscle Physiology and Disorders (4 papers), Statistical Methods in Clinical Trials (4 papers) and Pulmonary Hypertension Research and Treatments (4 papers). Lutz Harnisch is often cited by papers focused on Muscle Physiology and Disorders (4 papers), Statistical Methods in Clinical Trials (4 papers) and Pulmonary Hypertension Research and Treatments (4 papers). Lutz Harnisch collaborates with scholars based in United States, United Kingdom and Switzerland. Lutz Harnisch's co-authors include S. Y. Amy Cheung, Thomas Kerbusch, Bengt Hamrén, Alexander Staab, Valérie Cosson, Norbert Frey, Rolf Burghaus, Jörg Lippert, Sandra A. G. Visser and Marylore Chenel and has published in prestigious journals such as Blood, Pharmaceutical Research and Clinical Pharmacology & Therapeutics.

In The Last Decade

Lutz Harnisch

30 papers receiving 562 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lutz Harnisch United States	10	140	107	78	76	73	31	574
Matt Hutmacher United States	11	127 0.9×	155 1.4×	57 0.7×	68 0.9×	40 0.5×	15	618
Valérie Cosson Switzerland	12	154 1.1×	121 1.1×	84 1.1×	75 1.0×	60 0.8×	25	725
Matthew M. Hutmacher United States	14	92 0.7×	168 1.6×	44 0.6×	41 0.5×	40 0.5×	31	554
Daniela J. Conrado United States	15	110 0.8×	52 0.5×	42 0.5×	57 0.8×	66 0.9×	35	509
Shashi Amur United States	17	221 1.6×	84 0.8×	100 1.3×	80 1.1×	73 1.0×	25	999
Kenneth G. Kowalski United States	11	57 0.4×	159 1.5×	73 0.9×	46 0.6×	50 0.7×	24	526
Kevin Dykstra United States	12	95 0.7×	57 0.5×	70 0.9×	42 0.6×	69 0.9×	23	523
Lisa J. Benincosa United States	14	248 1.8×	161 1.5×	84 1.1×	92 1.2×	58 0.8×	29	804
Alan M. Hochberg United States	10	119 0.8×	51 0.5×	45 0.6×	66 0.9×	41 0.6×	18	611
Carol Cronenberger United States	13	67 0.5×	46 0.4×	135 1.7×	47 0.6×	101 1.4×	28	540

Countries citing papers authored by Lutz Harnisch

Since Specialization

Citations

This map shows the geographic impact of Lutz Harnisch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lutz Harnisch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lutz Harnisch more than expected).

Fields of papers citing papers by Lutz Harnisch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lutz Harnisch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lutz Harnisch. The network helps show where Lutz Harnisch may publish in the future.

Co-authorship network of co-authors of Lutz Harnisch

This figure shows the co-authorship network connecting the top 25 collaborators of Lutz Harnisch. A scholar is included among the top collaborators of Lutz Harnisch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lutz Harnisch. Lutz Harnisch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dingman, Robert, Jeanne Mendell, Katy C. Norman, et al.. (2025). Comparison of Model‐Predicted and Observed Evinacumab Pharmacokinetics and Efficacy in Children Aged < 5 Years With Homozygous Familial Hypercholesterolemia. CPT Pharmacometrics & Systems Pharmacology. 14(11). 1835–1847. 1 indexed citations

Dingman, Robert, Jeanne Mendell, Yuhuan Wang, et al.. (2025). Population Pharmacokinetics and Exposure‐Response Modeling for Evinacumab in Children, Adolescents, and Adults With Homozygous Familial Hypercholesterolemia. CPT Pharmacometrics & Systems Pharmacology. 14(11). 1823–1834. 2 indexed citations

Mendell, Jeanne, et al.. (2024). Population pharmacokinetic analyses of pozelimab in patients with CD55-deficient protein-losing enteropathy (CHAPLE disease). Journal of Pharmacokinetics and Pharmacodynamics. 51(6). 905–917. 2 indexed citations

Turner, K. C., et al.. (2024). Population Pharmacokinetics of Casirivimab and Imdevimab in Pediatric and Adult Non-Infected Individuals, Pediatric and Adult Ambulatory or Hospitalized Patients or Household Contacts of Patients Infected with SARS-COV-2. Pharmaceutical Research. 41(10). 1933–1949. 1 indexed citations

Turner, K. C., et al.. (2024). Population Pharmacokinetics of Fasinumab in Healthy Volunteers and Patients With Pain Due to Osteoarthritis of the Knee or Hip. Clinical Pharmacology in Drug Development. 13(6). 621–630. 1 indexed citations

Neelakantan, Srividya, et al.. (2023). Disease progression modeling of the North Star Ambulatory Assessment for Duchenne Muscular Dystrophy. CPT Pharmacometrics & Systems Pharmacology. 12(3). 375–386. 3 indexed citations

Purohit, Vivek S., et al.. (2022). Population PK and PD Analysis of Domagrozumab in Pediatric Patients with Duchenne Muscular Dystrophy. Clinical Pharmacology & Therapeutics. 112(6). 1291–1302. 7 indexed citations

Riley, Steve, et al.. (2021). Modeling of Survival and Frequency of Cardiovascular-Related Hospitalization in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis. American Journal of Cardiovascular Drugs. 21(5). 535–543. 10 indexed citations

Riley, Steve, et al.. (2021). Population pharmacokinetic modelling and simulation of tafamidis in healthy subjects and patients with transthyretin amyloidosis. British Journal of Clinical Pharmacology. 87(9). 3574–3587. 1 indexed citations

10.

Chanu, Pascal, Xiang Gao, René Bruno, Laurent Claret, & Lutz Harnisch. (2019). A modeling and simulation-based assessment of the impact of confounding factors on the readout of a sildenafil survival trial in pulmonary arterial hypertension. Journal of Pharmacokinetics and Pharmacodynamics. 46(5). 499–509. 2 indexed citations

11.

Schoemaker, Rik C., Satyaprakash Nayak, Lutz Harnisch, & Mats O. Karlsson. (2019). Modeling and simulation of the modified Rankin Scale and National Institutes of Health Stroke Scale neurological endpoints in intracerebral hemorrhage. Journal of Pharmacokinetics and Pharmacodynamics. 46(5). 473–484.

12.

Shafer, Frank, et al.. (2018). Dose Selection Process for Younger Children Participating in a Phase 3 Study to Evaluate the Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Patients with Sickle Cell Disease. Blood. 132(Supplement 1). 3643–3643. 4 indexed citations

13.

Wilkins, Justin, P Chan, Michael K. Smith, et al.. (2017). Thoughtflow: Standards and Tools for Provenance Capture and Workflow Definition to Support Model‐Informed Drug Discovery and Development. CPT Pharmacometrics & Systems Pharmacology. 6(5). 285–292. 6 indexed citations

14.

Vizza, Carmine Dario, B.K.S. Sastry, Zeenat Safdar, et al.. (2017). Efficacy of 1, 5, and 20 mg oral sildenafil in the treatment of adults with pulmonary arterial hypertension: a randomized, double-blind study with open-label extension. BMC Pulmonary Medicine. 17(1). 44–44. 16 indexed citations

15.

Harnisch, Lutz, et al.. (2017). Dose Selection Based on Modeling and Simulation for Rivipansel in Pediatric Patients Aged 6 to 11 Years With Sickle Cell Disease. CPT Pharmacometrics & Systems Pharmacology. 6(12). 845–854. 4 indexed citations

16.

Burghaus, Rolf, Valérie Cosson, S. Y. Amy Cheung, et al.. (2015). Good Practices in Model‐Informed Drug Discovery and Development: Practice, Application, and Documentation. CPT Pharmacometrics & Systems Pharmacology. 5(3). 93–122. 257 indexed citations

17.

Grieve, Andrew P., J. Curram, Lutz Harnisch, et al.. (2013). Advancing Clinical Trial Design in Pulmonary Hypertension. Pulmonary Circulation. 3(1). 217–225. 14 indexed citations

18.

Harnisch, Lutz, et al.. (2013). Modeling and Simulation as a Tool to Bridge Efficacy and Safety Data in Special Populations. CPT Pharmacometrics & Systems Pharmacology. 2(2). 1–4. 33 indexed citations

19.

Roethig, Hans J., et al.. (1996). The Effect of Activated Charcoal and Cholestyramine on the Pharmacokinetics of Leflunomide. Clinical Pharmacology & Therapeutics. 59(2). 204–204. 4 indexed citations

20.

Weber, Willi, et al.. (1993). Population kinetics of gentamicin in neonates. European Journal of Clinical Pharmacology. 44(S1). S23–S25. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact